Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC.
1/5 보강
Drug resistance continues to be a significant challenge in cancer treatment, responsible for over 90% of worldwide cancer-related deaths.
APA
Kwabiah D, Nagati V, Tripathi MK (2025). Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC.. Drug discovery today, 30(9), 104439. https://doi.org/10.1016/j.drudis.2025.104439
MLA
Kwabiah D, et al.. "Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC.." Drug discovery today, vol. 30, no. 9, 2025, pp. 104439.
PMID
40716510 ↗
Abstract 한글 요약
Drug resistance continues to be a significant challenge in cancer treatment, responsible for over 90% of worldwide cancer-related deaths. Transcription factors (TFs), which control vital cellular processes, also play a crucial role in cancer development and resistance. In hepatocellular carcinoma (HCC), resistance to sorafenib, a primary targeted therapy, significantly impairs treatment effectiveness and worsens patient outcomes. Among TFs, Y-box binding protein 1 (YBX1) has been recognized as a regulator of aggressive cancer traits in colorectal and breast cancers. However, its role in HCC and sorafenib resistance remains unclear. This review examines YBX1's role in HCC progression and drug resistance, its underlying molecular mechanisms, and its potential as a biomarker and therapeutic target for overcoming sorafenib resistance.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.